Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) announced the appointment of Fred Driscoll as interim CFO, as part of a strategic restructuring to enhance capital efficiency and focus on key programs. The company is reallocating resources to support its integrated discovery platform and advance pipeline programs, particularly NVD200 for COVID-19 prevention and treatment. This transition follows the departure of Jane Pritchett Henderson and Eric Kimble, who are leaving to pursue other opportunities. An executive search for a permanent CFO and a business development executive is underway.
Invivyd (Nasdaq: IVVD) announced four poster presentations at ID Week 2022, showcasing findings from studies on adintrevimab. Key posters include:
- Poster 226: Higher Doses of Adintrevimab for COVID-19 treatment - Phase 1 preliminary results.
- Poster 591: Population Pharmacokinetics of Adintrevimab in clinical study participants.
- Poster 1113: Clinical outcomes with Early Adintrevimab Therapy in COVID-19.
- Poster 1132: Characterizing Viral Dynamics after Adintrevimab administration.
Adintrevimab remains investigational, showing promise against COVID-19 variants.
Invivyd, formerly Adagio Therapeutics, has generated multiple candidate antibodies for COVID-19 prevention and treatment. Their integrated discovery platform has produced NVD200, a novel combination of two monoclonal antibodies, set to enter clinical trials in Q1 2023. These antibodies show broad in vitro neutralization against a range of SARS-CoV-2 variants, including Omicron sublineages and SARS-CoV-1. Invivyd aims to provide enhanced protection from serious viral diseases through innovative antibody engineering, targeting non-overlapping epitopes to reduce immune pressure.
Invivyd, formerly Adagio Therapeutics, announced a name change reflecting its focus on developing anti-viral antibodies that enhance immunity against viral diseases, starting with COVID-19. The company will trade under the new ticker symbol IVVD on Nasdaq starting September 13, 2022. Invivyd aims to deliver effective antibody solutions through its advanced discovery platform, which integrates evolutionary virology and antibody engineering. Additionally, the company is working on multiple candidates for seasonal influenza prevention.